Episode #23: Measuring the return from pharmaceutical innovation report 2022

Karen and guests dissect the findings from the latest annual R&D ROI report which launched last month. This report has provided insights into the state of biopharma R&D since 2010. We have expanded the analysis over time and our data set now covers the top 20 pharma companies by R&D spend.

Episode 23 features:

• Karen Taylor, Research Director, Centre for Health Solutions
• Naveed Panjwani, Director, UK Life Sciences Consulting
• Kevin Dondarski, Partner, US Life Sciences Strategy

Our annual R&D ROI report series analyses the projected return on investment that 20 leading biopharma companies can expect to earn from their late-stage pipelines as well as their pipeline composition and sources of innovation. As discussed in the report, it is clear that revitalising clinical trials through digitalisation could help to create a more seamless experience for patients and staff as well as drastically improve trial efficiency, enhance scientific rigor and expand health equity.

Listen to hear more on this topic.

Find out more

If you are interested in any of the topics discussed during this episode and want more information, please explore some useful links below:

• Stay up to date on industry issues by subscribing to our blog
• Seize the digital momentum - Measuring the return from pharmaceutical innovation 2022 report

Life Sciences Connect

To see the full collections of episodes so far, please visit the Life Sciences Connect podcast library.